Krystal Biotech, Inc.
KRYS
$193.84
-$6.13-3.07%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.51% | 116.09% | 247.53% | 473.02% | 2,722.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.51% | 116.09% | 247.53% | 473.02% | 2,722.79% |
| Cost of Revenue | 19.03% | 106.79% | 311.21% | 548.38% | 7,964.13% |
| Gross Profit | 57.36% | 116.78% | 243.64% | 468.12% | 2,582.53% |
| SG&A Expenses | 27.66% | 25.16% | 19.80% | 15.49% | 9.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.75% | 27.84% | 32.32% | 26.61% | 22.57% |
| Operating Income | 143.47% | 3,670.42% | 342.51% | 206.18% | 147.98% |
| Income Before Tax | 225.68% | 55.70% | 133.44% | 639.37% | 292.55% |
| Income Tax Expenses | -337.75% | 801.97% | 615.57% | 215.37% | -- |
| Earnings from Continuing Operations | 279.80% | 38.50% | 116.86% | 715.58% | 275.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 279.80% | 38.50% | 116.86% | 715.58% | 275.67% |
| EBIT | 143.47% | 3,670.42% | 342.51% | 206.18% | 147.98% |
| EBITDA | 134.37% | 1,937.22% | 362.89% | 213.27% | 151.83% |
| EPS Basic | 275.94% | 35.29% | 118.34% | 1,619.49% | 233.16% |
| Normalized Basic EPS | 94.94% | 440.38% | 625.72% | 263.83% | 174.36% |
| EPS Diluted | 277.27% | 34.98% | 122.84% | 3,746.21% | 220.14% |
| Normalized Diluted EPS | 95.51% | 439.69% | 604.04% | 258.35% | 172.05% |
| Average Basic Shares Outstanding | 1.45% | 1.85% | 3.35% | 5.33% | 7.24% |
| Average Diluted Shares Outstanding | 1.43% | 2.37% | 4.96% | 7.84% | 10.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |